Background: In type 2 diabetes mellitus
INTRODUCTION

Type 2 diabetes mellitus (T2DM) is characterized
by hyperglycemia related to a progressive loss of beta cell function [1] . The selection of initial antihyperglycemic therapy influences treatment failure and the need for additional therapy in individuals with T2DM [2] . Metformin and sulfonylureas are the two most commonly prescribed oral antihyperglycemic agents for initial therapy for T2DM because of their welldefined clinical profiles and cost [3] . These agents work by distinct mechanisms, with metformin primarily reducing hepatic glucose production and insulin resistance, and sulfonylureas stimulating insulin release by binding to their receptor on the pancreatic beta cell. In recently diagnosed patients with T2DM, monotherapy treatment with the sulfonylurea, glyburide, was associated with an increased likelihood of treatment failure compared with metformin (and rosiglitazone) over 4 years [4] . Despite a larger initial (within 6 months) increase in beta cell function with glyburide, greater treatment failure with glyburide was related to a greater decline in beta cell function overall relative to metformin (and rosiglitazone) [4, 5] .
Beta cell function also declines with aging [6] .
In older individuals with T2DM, sulfonylurea use tends to increase and metformin use declines [7] [8] [9] . Given the greater loss of beta cell function over time with sulfonylureas and the reduced beta cell function associated with aging, the present retrospective observational study was performed to examine the influence of initial monotherapy with metformin or a sulfonylurea on the subsequent use of insulin therapy in older subjects with T2DM.
Observational studies are used to estimate treatment effects when randomized controlled trials are not feasible. However, the lack of randomization may lead to imbalances in subject characteristics due to channeling bias [10] . Differences in baseline characteristics must be adjusted for in order to minimize channeling bias and determine treatment effect. Propensity score matching is a statistical technique used to generate well-defined cohorts matched on specific baseline characteristics in order to control for potential confounding [11] .
Therefore, the present analysis used propensity score matching to generate two well-matched cohorts of older subjects initially treated with metformin or a sulfonylurea.
METHODS
Study Design and Subject Selection
Data for this retrospective cohort study of US subjects were obtained using GE Healthcare's Clinical Data Services electronic medical record database. For the index period of January 1, 2003 to December 31, 2008, subjects with newly or previously diagnosed T2DM were included in the analysis if they were at least 65 years of age, received their first prescription for metformin or sulfonylurea as monotherapy during the index period, and continued monotherapy for at least 90 days following the index date (i.e., date of first prescription, Fig. 1 ). Subjects also had to have no prescriptions for any antihyperglycemic agents within the 1-year period prior to the index date, and were required to be continually enrolled in the database for at least 1 year before the index date (i.e., baseline data), and to have at least 1 year of follow-up data. The follow-up period was censored at the end of 2009 or the date of the subjects' latest available data. 
Outcomes
The proportion of subjects initiating insulin therapy during the 1-year follow-up period was the primary outcome of interest. Factors influencing the likelihood of or time to initiating insulin therapy were also evaluated.
The time from initial oral monotherapy with metformin or sulfonylurea to insulin initiation was estimated based on prescription records. Additional analyses extended the follow-up period to 2 or 3 years.
Statistical Analysis
To control for confounding, propensity score matching was used to generate matched cohorts of subjects treated with metformin or sulfonylurea monotherapy and at least 1 year of follow-up data. A multivariate logistic regression model was constructed first to calculate the propensity score, defined as the conditional probability of initiating sulfonylurea versus metformin monotherapy as a function of all measured baseline factors described above. A one-to-one greedy matching algorithm was employed as the next step to match propensity scores of the two treatment cohorts from best to next best [12] . Best matches were defined as pairs 
RESULTS
Of the 20,764 older subjects with T2DM who received their first prescription with metformin or sulfonylurea and had at least 1 year of follow-up data, matched cohorts of 6,018 subjects per treatment were generated using propensity score matching (Table 1) . Baseline demographics, laboratory measures, and comorbid conditions for these well-matched cohorts are shown in Table 2 . Briefly, these subjects (50% male) had a mean age of 75 years, mean body mass index of 31 kg/m 2 , and mean HbA 1c of 7.2% ( Table 2 ). The proportion of subjects initiating insulin within 1 year was significantly higher (2.8% vs.
1.4%; P\0.001) with sulfonylurea compared to metformin (Fig. 2) . After adjusting for baseline characteristics, the likelihood of initiating insulin therapy within 1 year of follow-up was higher in subjects who started with sulfonylurea monotherapy than with metformin (adjusted OR 1.82, 95% confidence interval [CI] 1.40-2.38; P\0.001). Higher HbA 1c and elevated serum creatinine were also associated with initiating insulin therapy (Table 3) . Male gender was associated with a lower likelihood of initiating insulin therapy. Sulfonylurea use was also associated with a shorter time to initiating insulin therapy compared to metformin (adjusted hazards ratio 2.10, 95% CI 1.83-2.39; P\0.001) ( Table 4 ). Higher HbA 1c and elevated serum creatinine were associated with a shorter time to initiating insulin therapy (Table 4) . In an analysis using matched cohorts with at least 2 years of follow-up data (n = 4,691 per treatment), significantly more subjects initiated with sulfonylurea therapy started insulin therapy compared to those initiated with metformin ( Fig. 2) . After adjusting for baseline characteristics for this cohort, the likelihood of initiating insulin therapy within 2 years of follow-up was higher in subjects initiated with sulfonylurea than with metformin (adjusted OR 2.27, 95% CI 1.82-2.82; P\0.001).
Similar results were identified for a matched cohorts with at least 3 years of follow-up data (n = 3,312 per treatment). Significantly more subjects initiated with sulfonylurea therapy started insulin therapy compared to those initiated with metformin (Fig. 2) . After adjusting for baseline characteristics for this cohort, the likelihood of initiating insulin therapy within 3 years of follow-up was also higher in subjects initiated with sulfonylurea than with metformin (adjusted OR 1.98, 95% CI 1.59-2.45; P\0.001).
DISCUSSION
The present study evaluated the effect of initial treatment with metformin or sulfonylurea monotherapy on subsequent treatment intensification with insulin therapy in US subjects with T2DM and aged C65 years. Older adults with T2DM were examined because older age is associated with reduced beta cell function Fig. 2 Proportion of subjects who initiated insulin within 1, 2, or 3 years after starting monotherapy with metformin or sulfonylurea (see text for number of subjects per treatment group at each time point) [6] . Thus, any treatments with negative effects on beta cell function may increase the requirement for insulin therapy in this population. Comparisons between treatments may be confounded by channeling bias and the present study attempts to control for this by using propensity score matching [10] . In the present study in two well-matched groups of older subjects, approximately twice as many subjects initiated insulin therapy within 1, 2, or 3 years of receiving their first prescription for sulfonylurea monotherapy compared with metformin monotherapy. The annualized rates of insulin initiation were approximately 1.5% for those started with metformin and 3% for those started with sulfonylureas. These rates on insulin initiation are generally similar to the annualized rates reported for a Canadian (1%) and a Swedish cohort (3.5%) of patients who initiated therapy with an oral antihyperglycemic agent [13, 14] . Furthermore, initiating treatment with sulfonylurea monotherapy was significantly associated with a shorter time to insulin use compared to initiating with metformin monotherapy.
The present results in US subjects are generally consistent with those in cohort studies from other countries. In a cohort of older Canadian subjects with T2DM (age C 66 years), new users of insulin secretagogues (including sulfonylureas) were more likely to initiate insulin therapy than new users of metformin [13] . In a Swedish cohort of subjects with T2DM, initial metformin monotherapy use was associated with a lower probability of initiating insulin relative to nonmetformin therapy (primarily sulfonylurea) [14] .
In a German cohort, treatment with a sulfonylurea was associated with a higher probability of initiating insulin therapy compared with metformin [15] . Furthermore, initial monotherapy with sulfonylurea led to more subsequent use of insulin relative to metformin use in cohorts from Scotland [16] and Canada [17] . Although these studies did not specifically match cohorts of initial metformin and sulfonylurea users for baseline characteristics, it is apparent that sulfonylurea use relative to metformin is an important factor contributing to the initiation of insulin therapy. Secondary failure occurs with all types of antihyperglycemic treatments [2, 4, 18] .
Secondary failure with sulfonylureas has been associated with desensitization of insulin secretion to prolonged exposure to sulfonylureas [19] and sulfonylurea-induced apoptosis of the beta cell [20] [21] [22] . Conversely, metformin reduces hepatic glucose output and increases insulin sensitivity; thus potentially reducing the burden on the beta cell to secrete insulin. The results of the present study suggest that selecting a treatment that is not associated with negative effects on an underlying pathophysiology of T2DM (i.e., declining beta cell function) prolongs the time from treatment initiation to intensification with insulin therapy. The difference may even be greater depending on the type of sulfonylurea, as there are differences in secondary failure within this class [23] . Baseline factors were also associated with initiating insulin therapy, including worse glycemic control and elevated serum creatinine.
Higher HbA 1c was a significant factor leading to insulin initiation in other cohort studies [14] [15] [16] . These factors may have precipitated more office visits and, hence, more opportunity for physicians to intensify or alter antihyperglycemic treatment with insulin.
There are several strengths and limitations related to this analysis. With regard to strengths, the study included large, well-matched cohorts of [6,000 subjects per treatment with at least 1 year of follow-up data. Similar findings in matched cohorts with 2 or 3 years of follow-up data also lend support to the robustness of the present findings. However, the following limitations need to be considered when interpreting the present results. This was a retrospective study and subjects were not randomly assigned to initial treatments.
Although propensity score matching generated well-matched cohorts, additional factors that were not available from the data and, thus, were not accounted for (e.g., measures of ontreatment glycemic control, duration of diabetes) may have influenced the results.
Subjects were only required to be on monotherapy for 90 days for inclusion in the analysis population, and subsequent discontinuation or switching of initial therapy or prescriptions for additional oral antihyperglycemic therapies were not accounted for in this analysis. This approach is similar-tointent to treat within clinical trial studies. Finally, changes in treatment paradigms for T2DM and the availability of additional antihyperglycemic Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
